Safety, Tolerability, and Pharmacokinetics, of Single and Multiple Dose of SAM-531 Administered Orally To Healthy Young and Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2015
At a glance
- Drugs Cerlapirdine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Wyeth
- 10 Jul 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jan 2009 Status changed from not yet recruiting to recruiting s reported by ClinicalTrials.gov.
- 20 Jan 2009 Actual initiation date (Aug 2008) added as reported by ClinicalTrials.gov.